|
| Press Releases |
|
 |
|
| Tuesday, December 26, 2017 |
|
|
Nanobiotix: 2017 review and 2018 expected milestones |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today provides a recap of its activities and achievements in 2017 and an overview of its anticipated 2018 milestones. more info >> |
|
|
FDA approves Nanobiotix's first Immuno-Oncology trial |
| A Phase I/II Study of NBTXR3 Activated by Radiation Therapy (SABR) for Patients with Non-Small Cell Lung Cancer or Head and Neck Squamous Cell Carcinoma Cancer Treated with an Anti-PD1 Antibody (Nivolumab or Pembrolizumab) more info >> |
|
| Monday, November 13, 2017 |
|
|
Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, recently presented positive clinical and preclinical data from the ongoing immuno-oncology programs. These data were presented at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held from November 8 to 12, 2017 in National Harbor, Maryland, USA. more info >> |
|
| Friday, November 10, 2017 |
|
|
Nanobiotix provides update on the global development of its lead product NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today provides an update on the global development of its lead product, NBTXR3. more info >> |
|
| Monday, October 23, 2017 |
|
|
Nanobiotix Completes Patient Inclusion for Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it has completed patient inclusion for the Phase II/III trial (Act.In.Sarc) of its lead product candidate, NBTXR3, in soft tissue sarcoma. The last patients are expected to start their treatment in two to three weeks. more info >> |
|
| Friday, September 29, 2017 |
|
|
Nanobiotix plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S. |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced today its intention to start a new trial in the company's immuno-oncology (IO) program. The trial is aimed at expanding the potential of NBTXR3 to recurrent and metastatic disease. more info >> |
|
| Friday, September 1, 2017 |
|
|
Nanobiotix half year results for the six months ended 30 June 2017 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its half year results for the six months ended 30 June 2017. more info >> |
|
| Friday, June 16, 2017 |
|
|
NANOBIOTIX: New Translational Data Presented at ASTRO, NCI and SITC's Immunotherapy Workshop |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today presented new translational data at the "Immunotherapy workshop - Incorporating Radiation Oncology into Immunotherapy" co-sponsored by the American Society of Radiation Oncology (ASTRO), the National Cancer Institute (NCI) and the Society for Immunotherapy of Cancer (SITC), that takes place from June 15 to 16, 2017 in Bethesda, Maryland, USA. more info >> |
|
| Tuesday, June 6, 2017 |
|
|
NANOBIOTIX: Promising Data from Phase I/II Head and Neck Cancer Trial with NBTXR3 Presented at the American Society of Clinical Oncology's Annual Meeting |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, presented the results of the Phase I/II head and neck cancer trial with its lead product candidate, NBTXR3, at the American Society of Clinical Oncology (ASCO), Chicago. more info >> |
|
| Thursday, May 18, 2017 |
|
|
Nanobiotix Announces First Positive Human Data Showing That NBTXR3 Could Become a Backbone in Immuno-Oncology |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its first set of clinical data from its immuno-oncology (IO) program, showing the potential ability of NBTXR3 to transform "cold" tumors into "hot" tumors. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
NEC Develops Physical AI That Anticipates Human Movement and Psychological States
Mar 12, 2026 16:41 JST
|
|
|
Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY(R) in Mainland China, Addressing Unmet Need in Moderately to Severely Active Ulcerative Colitis
Mar 12, 2026 15:14 JST
|
|
|
エーザイ、『Pokemon Sleep』とのコラボレーションで眠りの大切さを広く伝える啓発活動を開始
Mar 12, 2026 12:10: JST
|
|
|
More than 1,000 top buyers to attend! Procurement opportunities at China Chaoshan International Textile and Garment Exhibition
Mar 12, 2026 12:00: JST
|
|
|
Honda、「ジャパンインターナショナルボートショー2026」出展概要を発表
Mar 12, 2026 12:00: JST
|
|
|
Axonex Intelligence and Synergy Technology Group Form Joint Venture to Accelerate Digital Twin and Drone Flight Control Expansion
Mar 12, 2026 11:43 HKT/SGT
|
|
|
Axonex Intelligence與互惠智科有限公司共同成立合資企業
Mar 12, 2026 11:34 HKT/SGT
|
|
|
Axonex Intelligence与互惠智科有限公司共同成立合资企业
Mar 12, 2026 11:17 HKT/SGT
|
|
|
NEC and The University of Tokyo calculate carbon accumulation rates in Malaysian national park with a 9.4% margin of error
Mar 12, 2026 12:02 JST
|
|
|
More than 1,000 top buyers to attend! Procurement opportunities at China Chaoshan International Textile and Garment Exhibition
Mar 12, 2026 11:00 HKT/SGT
|
|
|
Japantastics Introduces the World of Kodaimoji, Bringing Ancient Characters into Modern Spaces
Mar 12, 2026 11:00 JST
|
|
|
テンストレント、完全オープンソーススタックを搭載した初のRISC-V AIワークステーション「TT-QuietBox(TM) 2」を発表。テラフロップス級推論を実現
Mar 12, 2026 01:00: JST
|
|
|
Tenstorrent Unveils TT-QuietBox(TM) 2, the First RISC-V AI Workstation With a Fully Open-Source Stack to Deliver Teraflop-Class Inference
Mar 12, 2026 01:00: JST
|
|
|
Tenstorrent Unveils TT-QuietBox(TM) 2, the First RISC-V AI Workstation With a Fully Open-Source Stack to Deliver Teraflop-Class Inference
Mar 12, 2026 00:00 HKT/SGT
|
|
|
Yuexiu REIT Maintains Operational Resilience, Revenue Exceeds RMB1.8 Billion in 2025
Mar 11, 2026 19:16 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
